Home » Newsletters » BioWorld Science

BioWorld Science

May 3, 2010

View Archived Issues

Novexel discloses novel antibacterial agents

Novel SAPK1/JNK1 inhibitors identified by U.S. researchers

Array BioPharma discloses novel receptor tyrosine kinase inhibitors

Janus kinase inhibitors for cancer therapy claimed by Rigel Pharmaceuticals

U.S. scientists identify novel viral and fungal inhibitors

IMPACT-DCM results encourage larger trials of cardiac repair cells in dilated cardiomyopathy

Polo-like kinase 1 inhibitors from Cyclacel active in xenograft cancer models

LigoCyte updates norovirus vaccine clinical development progress

Cleveland Biolabs describes novel curaxin radiosensitizers for cancer

Phase III study of Roche's taspoglutide in type 2 diabetes meets primary endpoint

Novavax reports results for seasonal influenza VLP vaccine candidate

Pepscan and Immunovo sign agreement for Pepscan's therapeutic vaccine portfolio

Mydicar meets primary endpoint in phase II advanced heart failure trial

BioTime to acquire ES Cell International for development of stem cell-based therapeutics

TxCell reports preliminary results from phase I/IIa trial of OvaSave in Crohn's disease

BioMarin plans phase III trial of GALNS in MPS IVA following phase I/II results

Phase III Trinity study results reported for olmesartan/amlodipine/HCTZ in hypertension

Artisan completes enrollment in phase IIb ART-123 study in sepsis patients

Dynavax receives clearance to start two phase III Heplisav trials

Pieris reports preclinical data for its c-Met Anticalin drug

Celtic Therapeutics acquires rights to Kiacta from BELLUS Health

EnzymeRx reports phase I results for pegsitacase

Provectus reports on end-of-phase II meeting with FDA for PV-10

BARDA exercises options on Cleveland BioLabs contract to develop CBLB-502

FDA approves Vimovo delayed-release tablets for arthritis patients

Palmitoylethanolamide enhances efficacy of topical ocular antihypertensive treatments

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...